The latest price target for Cyclerion Therapeutics (NASDAQ:CYCN) was reported by Truist Securities on October 20, 2021. The analyst firm set a price target for $14.00 expecting CYCN to rise to within 12 months (a possible 301.15% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Cyclerion Therapeutics (NASDAQ:CYCN) was provided by Truist Securities, and Cyclerion Therapeutics initiated their buy rating.

There is no last upgrade for Cyclerion Therapeutics

There is no last downgrade for Cyclerion Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cyclerion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cyclerion Therapeutics was filed on October 20, 2021 so you should expect the next rating to be made available sometime around October 20, 2022.

While ratings are subjective and will change, the latest Cyclerion Therapeutics (CYCN) rating was a initiated with a price target of $0.00 to $14.00. The current price Cyclerion Therapeutics (CYCN) is trading at is $3.49, which is within the analyst’s predicted range.